Taming cardiovascular risk: the promise of LDL cholesterol lowering therapeutics
European Pharmaceutical Review
FEBRUARY 1, 2024
That will be our pivotal trial for not just LDL lowering, but also for safety in Phase III, because it is a very large trial. He also founded the Chicago Center for Clinical Research, which became the largest investigator site in the US and was acquired by Pharmaceutical Product Development in 1996.
Let's personalize your content